Narimon Honarpour
Center for Global Development(US)Amgen (United States)(US)
Publications by Year
Research Areas
Lipoproteins and Cardiovascular Health, Health Systems, Economic Evaluations, Quality of Life, Cardiac pacing and defibrillation studies, Pharmaceutical Economics and Policy, Heart Failure Treatment and Management
Most-Cited Works
- → Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease(2017)5,779 cited
- → Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial(2014)724 cited
- → Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure(2020)627 cited
- → Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial(2017)587 cited
- → Cognitive Function in a Randomized Trial of Evolocumab(2017)473 cited
- → Effect of the Proprotein Convertase Subtilisin/Kexin 9 Monoclonal Antibody, AMG 145, in Homozygous Familial Hypercholesterolemia(2013)328 cited